The Phase III trials will evaluate survodutide in metabolic dysfunction-associated steatohepatitis (MASH), fibrosis and ...

The MHRA’s 2024/25 business plan focuses on improving service delivery for its customers, enabling access to new technologies ...

The long-acting injectable PrEP option is being rolled out at a record pace in sub-Saharan Africa and lower-income countries.

Innovent Biologics and ASK Pharm have signed a strategic partnership for the commercialisation of limertinib for the ...

NP001 is designed to tackle the neurodegenerative disease through an immunologic mechanism as opposed to a neurologic one.

The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of ...

The company intends to start a registrational Phase II trial of pelareorep and chemotherapy combination for breast cancer in ...

OnKure has announced the successful completion of its merger with Reneo Pharmaceuticals, with the combined entity set to ...

The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with relapsed or refractory T-cell leukaemia.

ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm specialising in pharmacometrics.

WuXi Biologics is also investigating interest in some of its European production facilities, which may be associated with ...

Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix for patient selection in PSMA targeted ...